

Biodiversity

Lundbeck does not operate in areas of high biodiversity value, nor do we source a significant number of natural resources from suppliers that adhere to a biodiversity policy or certification scheme. However, we acknowledge that pharmaceuticals in the environment, originating from our sold products, can have a negative impact on biodiversity and ecosystems.

Our commitment

Lundbeck recognizes biodiversity loss as one of the greatest threats to the natural world and takes the pressures on biodiversity seriously. Although Biodiversity is not currently classified as one of the company's material topics, we address risks to biodiversity primarily through our material topics of "Pollution Prevention" and "Climate Change Mitigation." We strive to enhance our understanding of how to measure the risks and impacts related to biodiversity. This ongoing effort enables us to monitor changes in the relevance of these issues within our environmental and business management practices each year.

We are committed to reducing our environmental impact by conducting risk assessments, optimizing our processes, and using the least harmful substances in our production. This commitment includes monitoring the environmental effects of the active pharmaceutical ingredients in our new medicinal products. Through necessary biological and physical/chemical studies, we assess the impact on various aquatic organisms as part of our Environmental Risk Assessment process. The knowledge gained drives our manufacturing processes.

Moreover, we uphold high ethical standards in animal welfare by adhering to strict legislation, systems, and routines. We use low-risk genetically modified organisms (GMO) in our research and development, ensuring that all organisms are kept enclosed in designated laboratories to prevent accidental introduction to the wild. All waste generated from this work is carefully managed and inactivated.

Lundbeck has also implemented several local initiatives at our production sites to safeguard biodiversity. These initiatives include creating wildflower beds, replanting forests, installing nesting boxes for birds, converting company-owned plots into wild nature areas, and minimizing the use of pesticides and fertilizers.

Additionally, our operations do not involve land-use change or exploitation that harms species' global extinction risk. We do not directly impact communities or indigenous people, and our sites are not located near biodiversity-sensitive areas. Our operations do not cause habitat deterioration, protected area disturbance, habitat fragmentation, land degradation, desertification, soil sealing, deforestation, or the introduction of invasive species.

Our future key challenges and opportunities:

- Support and implement local and national initiatives aimed at increasing biodiversity.
- Support initiatives to improve data quality and risk monitoring and minimize the presence and effects of pharmaceuticals in the environment, for example, by participating in European and national industry networks and actively engaging in the new Urban Wastewater Treatment Directive (UWWTD).
- Continuously minimize the use of raw materials and the generation of emissions and waste by optimizing our processes and recycling organic compounds.
- Reduce the presence of solvents and pharmaceuticals in wastewater and air emissions from our operations by substituting harmful substances and promoting clean emissions.
- Develop and maintain our environmental principles within the Lundbeck Supplier Standards, including auditing CMOs and chemical suppliers located in high-risk countries.
- Maintain an open and honest dialogue with our stakeholders by reporting our performance in our Annual Report and the Carbon Disclosure Project (CDP).